We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.875 | -8.18% | 9.825 | 9.55 | 10.10 | 10.10 | 10.00 | 10.10 | 1,056,126 | 16:35:13 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -7.04 | 58.38M |
From Apr 2019 to Apr 2024
TIDMETX
RNS Number : 7232G
e-Therapeutics plc
31 May 2017
e-Therapeutics plc
('e-Therapeutics' or the 'Company')
Results of Annual General Meeting
Oxford, UK, 31 May 2017 - e-Therapeutics plc (AIM: ETX) is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 8 May 2017 were duly passed by shareholders of the Company at the Annual General Meeting held earlier today.
-Ends-
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993 Ray Barlow, CEO 883 125 Steve Medlicott, Finance Director www.etherapeutics.co.uk Numis Securities Limited Tel: +44 (0) 207 260 Michael Meade / Freddie Barnfield 1000 (Nominated Adviser) www.numis.com James Black (Corporate Broking) Instinctif Partners Tel: +44 (0) 207 457 Melanie Toyne Sewell / Alex 2020 Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.
e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUARORBRAVOAR
(END) Dow Jones Newswires
May 31, 2017 09:01 ET (13:01 GMT)
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
